Current mRNA vaccines — developed by Modern and Pfizer — also elicit antibodies that react against multiple different coronaviruses, but at lower levels, Saunders said.
Eventually, the hope is that a pan-coronavirus vaccine could have an even broader response to help fight more divergent coronaviruses as well, Saunders said.
"Now, although these experiments [were] conducted in a nonhuman primate — and we always have to have a caveat when you’re dealing in a nonhuman primate — nonetheless, this is an extremely important proof of concept that we will be aggressively pursuing as we get into the development of human trials," Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases (and not involved with the work) said about this study at a White House Briefing on May 13.
"There's no data yet to say how this will translate to humans," Saunders said. But, "What's encouraging is that the vaccine was based off of an antibody that we found from a human."
Now, the researchers are hoping to design a small clinical trial to first test the safety of their vaccine in humans.
Market Data 
Markets 
AI
